Patents Assigned to Institute Curie
  • Publication number: 20240269282
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment and diagnosis of cancer. The invention also relates to methods and pharmaceutical compositions for the treatment of inflammatory diseases and autoimmune diseases. The inventors investigate the role and specific contribution of extracellular vesicles (EVs) in cancer environment. The inventors demonstrate that CSF1-associated EVs induce macrophage signature associated with T cell infiltration and extended patient survival. The inventors demonstrate that via specific extracellular vesicles, these tumors promote pro-inflammatory macrophages correlated with better clinical outcome and a better prognosis in TNBC patients. In the present invention, the inventors provide in vitro evidences towards a direct role of CSF1-associated EVs as tools, alone or with other immuno-therapies, to promote anti-tumor immune responses.
    Type: Application
    Filed: May 10, 2022
    Publication date: August 15, 2024
    Applicants: Institut Curie, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Clotilde Thery, Mercedes Tkach
  • Publication number: 20240247318
    Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
    Type: Application
    Filed: February 14, 2024
    Publication date: July 25, 2024
    Applicants: Institute Curie, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova
  • Publication number: 20240229122
    Abstract: The present disclosure relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising a step of subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence.
    Type: Application
    Filed: February 6, 2024
    Publication date: July 11, 2024
    Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite de Versailles Saint-Quentin-en-Yvelines
    Inventors: Charlotte Proudhon, Amélie Kasperek, Amanda Bortolini Silveira, François-Clément Bidard, Marc-Henri Stern
  • Publication number: 20240201192
    Abstract: The invention relates to tumor-associated FOLR2+ macrophages and gene signature thereof as a biomarker of favorable outcome and anti-tumor immunity useful for the prognosis and monitoring of cancer patients. The invention relates also to FOLR2+ macrophages as a therapeutic target for enhancing T cell immunity in the prevention and treatment of cancer and infectious diseases.
    Type: Application
    Filed: April 12, 2022
    Publication date: June 20, 2024
    Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite Paris Cite, Centre National de la Recherche Scientifique
    Inventors: Rodrigo Nalio Ramos, Pierre Guermonprez, Eliane Piaggio, Julie Helft
  • Publication number: 20240002776
    Abstract: The present invention relates to a device (2) for providing a liquid medium with a controlled flow rate and with a controlled concentration of a dissolved gas, the device (2) comprising: —a liquid reservoir (4) provided with: —at least one gas inlet (7); —at least one gas outlet (8); and—at least one liquid outlet (9); —an admission line (5) configured to provide a gaseous medium into the liquid reservoir (4), the admission line (5) being connected to the at least one gas inlet (7) and comprising at least one control valve (12); and an emission line (6) configured to withdraw the gaseous medium from the liquid reservoir (4), the emission line (6) being connected to the at least one gas outlet (8) and comprising at least one control valve (15). The present invention further relates to an assembly comprising said device, and to a method for providing a liquid medium with a controlled flow rate and with a controlled concentration in a dissolved gas.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 4, 2024
    Applicants: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut Curie, Fluigent
    Inventors: William Cesar, Charlotte Bouquerel, Marine Verhulsel, Jean-Louis Viovy, Stéphanie Descroix
  • Publication number: 20230303974
    Abstract: The present invention relates to an engineered immune cell defective for SOCS1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of SOCS1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 28, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Laurie Menger, Silvia Menegatti, Sebastian Amigorena
  • Publication number: 20230302050
    Abstract: The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 28, 2023
    Applicants: Institut Curie, Centre National de la Recherche Scientifique, The University of Zurich, Honing Biosciences
    Inventors: Sandrine Moutel, Franck Perez, Michele Bernasconi, Nagjie Laila Alijaj, Zélia Gouveia
  • Publication number: 20230293478
    Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: May 12, 2021
    Publication date: September 21, 2023
    Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer Institute
    Inventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
  • Publication number: 20230212243
    Abstract: The present application relates to a tumor specific neoantigenic peptide, wherein said peptide is encoded by a part of an ORF sequence from a transcript associated with a SF3B1 or a SF3B1-like mutation, comprises at least 8 amino acids and binds at least one MHC molecule with an affinity of less than 500 nM; and is not expressed in normal healthy cells. The present application further relates to vaccine or immunogenic composition, antibodies, T cell receptors, polynucleotides, vectors and immune cells derived thereof as well as their use in therapy of cancer.
    Type: Application
    Filed: May 12, 2021
    Publication date: July 6, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Olivier Lantz, Marc-Henri Stern, Jérémy Bigot, Alexandre Houy, Ana Ines Lalanne
  • Publication number: 20230183675
    Abstract: The present invention relates to the identification of a fully humanized single domain antibody scaffold as well as its use in generating synthetic single domain antibodies. The invention further relates to antigen-binding proteins comprising said single domain antibody scaffold and their use in therapy.
    Type: Application
    Filed: May 20, 2021
    Publication date: June 15, 2023
    Applicants: Institut Curie, Centre National de la Recherche Scientifique
    Inventors: Franck Perez, Sandrine Moutel
  • Publication number: 20230117652
    Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; and a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.
    Type: Application
    Filed: September 21, 2022
    Publication date: April 20, 2023
    Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite de Versailles Saint-Quentin-en-Yvelines
    Inventors: Charlotte Proudhon, Amélie Kasperek, Amanda Bortolini Silveira, François-Clément Bidard, Marc-Henri Stern
  • Publication number: 20230107291
    Abstract: The invention relates to a method of identification of functional disease-specific, in particular tumor-specific, regulatory T cells and markers thereof. The invention also relates to the derived functional tumor-specific regulatory T cells, markers and engineered regulatory T cells and to their use for the diagnosis, prognosis, monitoring and treatment of cancer.
    Type: Application
    Filed: February 22, 2021
    Publication date: April 6, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale, Institut Mutualiste Montsouris
    Inventors: Eliane Piaggio, Wilfrid Richer, Christine Sedlik, Jimena Tosello, Joshua Waterfall, Elisa Bonnin
  • Publication number: 20220401539
    Abstract: The present disclosure relates to a tumor specific neoantigenic peptide, wherein said peptide (i) is encoded by a part of an (ORF) sequence from an unannotated transcript which transcription is positively regulated by an aberrant fusion protein, and (ii) is expressed at a higher level or frequency in a sample from said tumor compared to normal tissue sample. The present disclosure also relates to vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.
    Type: Application
    Filed: October 22, 2020
    Publication date: December 22, 2022
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Olivier Delattre, Olivier Saulnier, Joshua Waterfall, Céline Collin, Julien Vibert, Maud Gautier
  • Patent number: 11439724
    Abstract: The invention relates to a device for adsorbing odours comprising an absorbent layer and an adsorbent layer, said adsorbent layer being provided with a material permeable to volatile organic compounds (VOCs) and an adsorbent particulate filler comprising at least one spice. Such a device is particularly useful for adsorbing and masking body odours.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: September 13, 2022
    Assignees: Institute Curie, Ecole Superieure De Physique Et De Chimie Industrielle (ESPCI), Ecole Nationale Superieure De Chimie De Paris (ENSCP), Centre National De La Recherche Scientifique, Cemag Care
    Inventors: Aurélie Thuleau, Isabelle Fromantin, Vincent Semetey, José Dugay, Jean-François Le Meur
  • Publication number: 20220193198
    Abstract: The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Eliane PIAGGIO, Sebastian AMIGORENA, Pamela CAUDANA, Felix REY, Gleyder ROMAN-SOSA, Pablo GUARDADO-CALVO
  • Patent number: 11236300
    Abstract: The present invention relates to a microfluidic device to manipulate, select, treat, or cultivate living bodies, comprising a first chamber, a second chamber and a network of guiding tracks, wherein: said network of guiding tracks comprises at least one first guiding track connecting the first chamber and the second chamber and at least one second guiding track connecting said at least one first guiding track with at least two interconnections; and said at least one second guiding track comprises a curved part; said curved part exhibiting a concavity facing the second chamber or the part of the network connected to the second chamber.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: February 1, 2022
    Assignees: Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de Paris
    Inventors: Catherine Villard, Jean-Louis Viovy, Renaud Renault, Jean-Baptiste Durand, Jean-Michel Peyrin, Ivan Ferrante
  • Patent number: 11149316
    Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: October 19, 2021
    Assignees: Institut Curie, INSERM (Institut National de la Sante et de la Recherche Medicale
    Inventors: Elodie Manie, Marc-Henri Stern, Tatiana Popova
  • Publication number: 20210246518
    Abstract: The present invention relates to a method for detecting the interaction in a cell between a RNA and a protein, wherein the cell expresses: —the RNA fused to a hairpin, called hairpin-tagged RNA, —the protein fused to a tag, called tagged-protein, —a reporter protein fused to a protein which binds to said hairpin, wherein said reporter protein is a luminescent reporter protein, said method comprises the lysis of the cell and the detection of the complex tagged protein/hairpin-tagged RNA/hairpin binding protein—reporter protein.
    Type: Application
    Filed: September 9, 2019
    Publication date: August 12, 2021
    Applicants: Centre National de la Recherche Scientifique, Institut Naitonal de la Sante et de la Recherche Medicale, Institut Curie
    Inventor: Alena Shkumatava
  • Patent number: 11077121
    Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: August 3, 2021
    Assignees: Institute For Cancer Research, Institut Curie, Institut de Genetique et de Biologie Moleculaire et Cellulaire
    Inventors: Alfonso Bellacosa, Rossella Tricarico, Tim Yen, Vikram Bhattacharjee, Pietro Mancuso, Lionel Larue, Irwin Davidson
  • Publication number: 20210161887
    Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
    Type: Application
    Filed: April 3, 2019
    Publication date: June 3, 2021
    Applicants: Universite de Bretagne Occidentale, Centre Hospitalier Regional Universitaire de Brest, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de Paris, Univ Paris XIII Paris-Nord Villetaneuse, Universite Paris-Saclay
    Inventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko